• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The Immune-Modulatory Properties of iPSC-Derived Antigen-Presenting Cells.诱导多能干细胞衍生的抗原呈递细胞的免疫调节特性
Transfus Med Hemother. 2020 Dec;47(6):444-453. doi: 10.1159/000512721. Epub 2020 Nov 16.
2
Effects of mesenchymal stem cells from human induced pluripotent stem cells on differentiation, maturation, and function of dendritic cells.人诱导多能干细胞来源的间充质干细胞对树突状细胞分化、成熟及功能的影响。
Stem Cell Res Ther. 2017 Mar 2;8(1):48. doi: 10.1186/s13287-017-0499-0.
3
Generation of mouse pluripotent stem cell-derived proliferating myeloid cells as an unlimited source of functional antigen-presenting cells.生成小鼠多能干细胞衍生的增殖性髓系细胞作为功能抗原呈递细胞的无限来源。
Cancer Immunol Res. 2015 Jun;3(6):668-77. doi: 10.1158/2326-6066.CIR-14-0117. Epub 2015 Feb 11.
4
Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications.癌症免疫治疗中树突状细胞的见解:从实验台到临床应用
Front Cell Dev Biol. 2021 Jun 28;9:686544. doi: 10.3389/fcell.2021.686544. eCollection 2021.
5
Concise Review: Towards the Clinical Translation of Induced Pluripotent Stem Cell-Derived Blood Cells-Ready for Take-Off.简明综述:诱导多能干细胞衍生血细胞的临床转化——蓄势待发。
Stem Cells Transl Med. 2019 Apr;8(4):332-339. doi: 10.1002/sctm.18-0134. Epub 2018 Dec 26.
6
Genetically modified dendritic cells in cancer therapy: implications for transfusion medicine.基因改造的树突状细胞在癌症治疗中的应用:对输血医学的启示
Transfus Med Rev. 2001 Oct;15(4):292-304. doi: 10.1053/tmrv.2001.26960.
7
Pro-inflammatory chitosan/poly(γ-glutamic acid) nanoparticles modulate human antigen-presenting cells phenotype and revert their pro-invasive capacity.促炎型壳聚糖/聚(γ-谷氨酸)纳米粒调节人抗原呈递细胞表型并逆转其促侵袭能力。
Acta Biomater. 2017 Nov;63:96-109. doi: 10.1016/j.actbio.2017.09.016. Epub 2017 Sep 14.
8
Induced pluripotent stem cells reprogrammed from primary dendritic cells provide an abundant source of immunostimulatory dendritic cells for use in immunotherapy.由原代树突状细胞重编程而来的诱导多能干细胞为免疫治疗提供了丰富的免疫刺激树突状细胞来源。
Stem Cells. 2020 Jan;38(1):67-79. doi: 10.1002/stem.3095. Epub 2019 Oct 31.
9
Modulation of human allogeneic and syngeneic pluripotent stem cells and immunological implications for transplantation.人同种异体和同基因多能干细胞的调控及其对移植的免疫学意义
Transplant Rev (Orlando). 2016 Apr;30(2):61-70. doi: 10.1016/j.trre.2016.02.001. Epub 2016 Feb 10.
10
Prospects and Challenges of Induced Pluripotent Stem Cells in Equine Health.诱导多能干细胞在马健康领域的前景与挑战。
Front Vet Sci. 2015 Nov 19;2:59. doi: 10.3389/fvets.2015.00059. eCollection 2015.

引用本文的文献

1
Chemical modification of uridine modulates mRNA-mediated proinflammatory and antiviral response in primary human macrophages.尿苷的化学修饰可调节原代人巨噬细胞中mRNA介导的促炎和抗病毒反应。
Mol Ther Nucleic Acids. 2022 Jan 10;27:854-869. doi: 10.1016/j.omtn.2022.01.004. eCollection 2022 Mar 8.
2
Continuous human iPSC-macrophage mass production by suspension culture in stirred tank bioreactors.悬浮培养搅拌罐生物反应器中人诱导多能干细胞源性巨噬细胞的连续大规模生产。
Nat Protoc. 2022 Feb;17(2):513-539. doi: 10.1038/s41596-021-00654-7. Epub 2022 Jan 17.
3
Neuroinflammation in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia and the Interest of Induced Pluripotent Stem Cells to Study Immune Cells Interactions With Neurons.肌萎缩侧索硬化症和额颞叶痴呆中的神经炎症以及诱导多能干细胞在研究免疫细胞与神经元相互作用方面的意义。
Front Mol Neurosci. 2021 Dec 14;14:767041. doi: 10.3389/fnmol.2021.767041. eCollection 2021.
4
Antigen-Presenting Cells: Potential of Proven und New Players in Immune Therapies.抗原呈递细胞:免疫治疗中已证实及新出现的参与者的潜力
Transfus Med Hemother. 2020 Dec;47(6):429-431. doi: 10.1159/000512729. Epub 2020 Nov 10.

本文引用的文献

1
Potential of immunotherapies in the mediation of antileukemic responses for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) - With a focus on Dendritic cells of leukemic origin (DC).免疫疗法在介导急性髓细胞白血病 (AML) 和骨髓增生异常综合征 (MDS) 患者抗白血病反应中的潜力 - 重点关注白血病来源的树突状细胞 (DC)。
Clin Immunol. 2020 Aug;217:108467. doi: 10.1016/j.clim.2020.108467. Epub 2020 May 26.
2
A 3D iPSC-differentiation model identifies interleukin-3 as a regulator of early human hematopoietic specification.一种 3D iPSC 分化模型将白细胞介素-3 鉴定为早期人类造血特化的调节剂。
Haematologica. 2021 May 1;106(5):1354-1367. doi: 10.3324/haematol.2019.228064.
3
Role of microRNAs in the Regulation of Dendritic Cell Generation and Function.miRNAs 在树突状细胞生成和功能调控中的作用
Int J Mol Sci. 2020 Feb 15;21(4):1319. doi: 10.3390/ijms21041319.
4
Induced pluripotent stem cell macrophages present antigen to proinsulin-specific T cell receptors from donor-matched islet-infiltrating T cells in type 1 diabetes.诱导多能干细胞巨噬细胞呈递抗原给来自 1 型糖尿病供体胰岛浸润 T 细胞的胰岛素原特异性 T 细胞受体。
Diabetologia. 2019 Dec;62(12):2245-2251. doi: 10.1007/s00125-019-04988-6. Epub 2019 Sep 12.
5
Dendritic cells in cancer immunology and immunotherapy.树突状细胞在癌症免疫和免疫治疗中的作用。
Nat Rev Immunol. 2020 Jan;20(1):7-24. doi: 10.1038/s41577-019-0210-z. Epub 2019 Aug 29.
6
T cell and dendritic cell interactions in lymphoid organs: More than just being in the right place at the right time.T 细胞和树突状细胞在淋巴器官中的相互作用:不仅仅是在正确的时间出现在正确的地方。
Immunol Rev. 2019 May;289(1):115-128. doi: 10.1111/imr.12753.
7
Concise Review: Towards the Clinical Translation of Induced Pluripotent Stem Cell-Derived Blood Cells-Ready for Take-Off.简明综述:诱导多能干细胞衍生血细胞的临床转化——蓄势待发。
Stem Cells Transl Med. 2019 Apr;8(4):332-339. doi: 10.1002/sctm.18-0134. Epub 2018 Dec 26.
8
Bioreactor-based mass production of human iPSC-derived macrophages enables immunotherapies against bacterial airway infections.基于生物反应器的大规模生产人诱导多能干细胞衍生巨噬细胞可用于针对细菌性气道感染的免疫疗法。
Nat Commun. 2018 Nov 30;9(1):5088. doi: 10.1038/s41467-018-07570-7.
9
Designer macrophages: Pitfalls and opportunities for modelling macrophage phenotypes from pluripotent stem cells.定制化巨噬细胞:从多能干细胞构建巨噬细胞表型的陷阱与机遇
Differentiation. 2018 Nov-Dec;104:42-49. doi: 10.1016/j.diff.2018.10.001. Epub 2018 Oct 16.
10
Studying tissue macrophages in vitro: are iPSC-derived cells the answer?体外研究组织巨噬细胞:iPSC 衍生细胞是答案吗?
Nat Rev Immunol. 2018 Nov;18(11):716-725. doi: 10.1038/s41577-018-0054-y.

诱导多能干细胞衍生的抗原呈递细胞的免疫调节特性

The Immune-Modulatory Properties of iPSC-Derived Antigen-Presenting Cells.

作者信息

Ackermann Mania, Dragon Anna Christina, Lachmann Nico

机构信息

Institute of Experimental Hematology, RG Translational Hematology of Congenital Diseases, REBIRTH - Research Center for Translational and Regenerative Medicine, Hannover Medical School, Hannover, Germany.

Institute for Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany.

出版信息

Transfus Med Hemother. 2020 Dec;47(6):444-453. doi: 10.1159/000512721. Epub 2020 Nov 16.

DOI:10.1159/000512721
PMID:33442339
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7768145/
Abstract

Antigen-presenting cells (APCs), such as dendritic cells (DCs) and macrophages, are important regulators of the immune system, as they connect the innate and adaptive immunity by critically regulating T-cell responses. Thus, APCs are involved in both tissue homeostasis and tolerance, but also coordinate immune responses in case of infection and inflammation. Primary APCs are commonly generated from peripheral blood-derived monocytes and have been used as cell therapeutics in several (pre-)clinical settings, e.g., immune oncology, however, with varying efficiency. One promising alternative to study antigen presentation in vitro and to develop novel cell-based therapies are induced pluripotent stem cells (iPSCs). IPSCs can nowadays be generated from a variety of different cell types using several refined reprogramming techniques. Given their unlimited proliferation and differentiation potential, they hold great promise for regenerative medicine, and recently, first iPSC derivatives have found their way into first clinical studies for cell-based therapies. In this review article, we will give a brief overview of current methods for the generation and applications of primary APCs, but also specifically focus on different strategies for the generation of defined subsets of DCs and macrophages from human PSCs. Moreover, we will highlight the potential but also hurdles for the clinical translation of iPSC-derived APCs.

摘要

抗原呈递细胞(APCs),如树突状细胞(DCs)和巨噬细胞,是免疫系统的重要调节因子,因为它们通过严格调节T细胞反应来连接先天免疫和适应性免疫。因此,APCs既参与组织稳态和耐受性,也在感染和炎症情况下协调免疫反应。原代APCs通常由外周血来源的单核细胞产生,并已在多种(临床前)临床环境中用作细胞疗法,例如免疫肿瘤学,但其效率各不相同。诱导多能干细胞(iPSCs)是一种在体外研究抗原呈递和开发新型细胞疗法的有前途的替代方法。如今,可以使用几种精细的重编程技术从多种不同细胞类型中生成iPSCs。鉴于其无限的增殖和分化潜力,它们在再生医学中具有巨大的前景,最近,首批iPSC衍生物已进入基于细胞疗法的首批临床研究。在这篇综述文章中,我们将简要概述原代APCs的生成方法和应用,还将特别关注从人多能干细胞生成特定DCs和巨噬细胞亚群的不同策略。此外,我们将强调iPSC衍生的APCs临床转化的潜力和障碍。